REG - IQ-AI Limited - Update on Collaboration Agreement with Mayo Clinic

IQ-AIAnnouncement

18/08/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230818:nRSR8096Ja&default-theme=true

RNS Number : 8096J  IQ-AI Limited  18 August 2023

18 August 2023

 

IQ-AI Ltd

("IQ-AI" or the "Company")

Update on Collaboration Agreement with Mayo Clinic

Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF)
announces that the collaboration agreement signed with the Mayo Clinic for the
development of IB Trax™ has concluded. The working relationship with the
Mayo Clinic remains unchanged and will continue. As a corollary of the
conclusion of the agreement, and in the spirit of the long-standing and
continuing relationship between both parties, The Mayo Foundation has reverted
the 396,241 shares previously issued to them per the terms of the agreement,
and the Company has agreed with its Broker, Peterhouse Capital, to sell these
shares in the market and to donate the entirety of the proceeds to charity.

--ENDS--

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFLFFAEDSESA